Opioid Pain Therapeutics Market to Reap Excessive Revenues by 2027

Opioid Pain Therapeutics Market - Introduction

Opioids are therapeutics prescribed by physicians to individuals suffering from chronic pain. These therapeutics are used in the treatment of chronic headaches, backache, pain associated with cancer, and injury. Opioids molecule link with the receptors present on the nerve cells and effectively help in pain management. However, regular use of opioids can lead to addiction and have harmful effects on the individual.

Opioids are often used to treat acute pulmonary edema associated with left ventricular failure. Major side effects of opioids are sleepiness, constipation, shallow breathing, slow heart rate, loss of consciousness, and nausea.Different types of opioids are prescribed for pain management such as codeine, fentanyl, hydrocodone, oxycodone, oxymorphone, and morphine. According to the American Society of Anesthesiologist report published in 2017, approximately 60% of millennials have experienced chronic pain.

Report Overview @ https://www.transparencymarketresearch.com/opioid-pain-therapeutics-market.html

The global opioid pain therapeutics market is driven by increase in patient population suffering from chronic pain, rise in sales of over-the-counter drugs, and surge in product development. However, increase in drug abuse, rise in opioid trafficking, and high risk of side effects are likely to be the major restraints of the global opioid pain management market during the forecast period.

Opioid Pain Therapeutics Market - Competitive Landscape

Janssen Pharmaceutical

Janssen Pharmaceutical is headquartered in Titusville, New Jersey, U.S. In 1961 Janssen Pharmaceutical was integrated into Johnson & Johnson .Janssen Pharmaceutical is amongst the leading pharmaceutical companies in the U.S. The company product portfolio includes therapeutics for pulmonary hypertension, infectious diseases, pain management, cardiovascular & metabolism, and oncology.

Get a Glimpse of the In-Depth Analysis through our Comprehensive "Opioid Pain Therapeutics Market" Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=67556

Teva Pharmaceutical

Teva Pharmaceutical is one of the leading generic drug manufacturers in the world. The company produced more than 120 billion capsules and tablets during 2018.According to reports 1 out of 9 generic prescription in the U.S. are Teva Pharmaceutical products. The company has a well-established distribution network spread throughout the globe with operation in more than 60 countries.

Mylan N.V.

Mylan N.V. was established in1961 and is headquartered in Canonsburg, Pennsylvania, U.S. Mylan N.V., and its subsidiaries develop, manufactures, and market generic over the counter drugs along with branded-generic pharmaceutical products throughout North America, Europe, and other parts of the globe. Mylan N.V. has well established strategic partnership and license agreements with some of the leading pharmaceutical manufacturer such as Pfizer Inc., Biocon Ltd., Kyowa Kirin Biologics Co. Ltd, and others

Perdue Pharma L.P.

Perdue Pharma L.P. was established in 1892 in Stamford, Connecticut, U.S. The company and its affiliates are engaged in production, development, and distribution of prescription and over-the-counter prescription and non-prescription medicines and healthcare products for individual suffering from chronic pain. Purdue Pharma L.P. was previously known as The Purdue Frederick Company which was later changed Purdue Pharma L.P. in January, 1991.

Pre Book "Opioid Pain Therapeutics Market" Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=67556<ype=S

Some of the other key players operating in the global Opioid Pain Therapeutics Market with significant developments include Allergan, AbbVie, QRxpharma Limited, Daiichi Sankyo Company, Endo Pharmaceuticals and other prominent players.

Opioid Pain Therapeutics Market - Dynamics

Increase in Patient population

Increase in patient population suffering from chronic pain, and growth of the pharmaceuticals industry coupled with growing demand are anticipated to drive the global opioid pain therapeutics market in the region during the forecast period. For instance, according to Centers for Disease Control and Prevention, nearly 20.4% adults (about 50 million) in the U.S. are suffering from chronic pain and 20 million have high impact chronic pain.

Technological advancement and new product lunch to drive the market

Increase in product launches, rise in strategic collaborations for expansion of business, and surge in demand are anticipated to drive the global opioid pain therapeutics market during the forecast period. For instance, in June 2018, Daiichi Sankyo Company, Limited launched Fentanyl Citrate Tape for treating moderate to severe pain caused by cancer. The product will be manufactured by Japan-based manufacturer Kyukyu Pharmaceutical Co., Ltd.

Asia Pacific is likely to present lucrative market opportunities

Asia Pacific is likely to present lucrative opportunities in the opioid pain therapeutics market during the forecast period. Increase in demand, rise in patient population, rapidly growing pharmaceutical industry in the developing countries in the region, and surge in the number of regional manufacturers are projected to drive the opioid pain therapeutics market in the region during the forecast period. Increase in government initiatives to regulate the use of opioids due to rise in drug abuse is anticipated to boost the growth of the global opioid pain therapeutics market in Asia Pacific.

Increase in drug abuse, along with rise in opioid trafficking is expected to hinder the market growth

Opioid therapeutics used for pain management are generally considered safe for use when taken for a short time as recommended by a physician, but in some cases they can be used for drug abuse as they produce elation in addition to pain relief. According to the National Institute of Drug Abuse it has been estimated that more than 130 individual in the U.S. die due to overdose of opioids. Therefore control the drug abuse of opioids many government organization are implementing stringent regulation for the sale of these drugs. Implementation of stringent regulation for the use of opioid is anticipated to affect the total sales opioid drugs as many physician would be reluctant in prescribing opioid even when it is medically applicable. For instance, in April 2019, China announced that it will consider all available variants of fentanyl opioid as controlled substances which is projected to slow down drug supply.

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.